Vaccine News and Research

Latest Vaccine News and Research

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

13 Jul 2010

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.

13 Jul 2010

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has named Case Western Reserve University School of Medicine as the lead institution of an International Center of Excellence for Malaria Research (ICEMR). The $7.9M seven-year grant will accelerate the control of malaria and help eliminate it worldwide.

13 Jul 2010

Wall Street Journal essay examines historical efforts to control malaria

In a Wall Street Journal essay, Sonia Shah, the author of an upcoming book on malaria, outlines the historical efforts to control malaria - from the Roman Empire through today.

13 Jul 2010

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.

12 Jul 2010

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.

12 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy. At a cost of at least $300 for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil- from Merck and Cervarix- from GlaxoSmithKline, are some of the most expensive ever introduced.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Diabetes reform plans do not please the AMA

In a bid to reform the way long term illnesses like diabetes are managed in Australia, the federal government announced a $436 million scheme to be introduced from 2012.

11 Jul 2010

UM researcher uses computer algorithms to develop vaccines for new strains of influenza viruses

Defeating the flu is challenging because the virus responsible for the disease undergoes frequent changes of its genetic code, making it difficult for scientists to manufacture effective vaccines for the seasonal flu in a timely manner. Now, a University of Miami computer scientist, Dimitris Papamichail, and a team of researchers from Stony Brook University have developed a rapid and effective approach to produce vaccines for new strains of influenza viruses.

9 Jul 2010

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Health and Human Services Secretary Kathleen Sebelius said Thursday "that she would provide $25 million more to help states buy life-saving medications for people with H.I.V. or AIDS. Advocates for patients said the money was not nearly enough to eliminate waiting lists, which have surged to record levels as people have lost health insurance, along with their jobs, and states have cut their budgets. Ms. Sebelius said she was 'reallocating and transferring $25 million in existing resources' to provide medicines for people on waiting lists.

9 Jul 2010

Merck to lay off 15 percent of workers, close plants, research facilities

Drugmaker Merck announced it is closing eight research centers and eight manufacturing plants and laying off 15,000 people from its worldwide operations during the next two years because of its merger with Schering-Plough. "The restructuring is expected to save $2.7 billion to $3.1 billion in 2012, the company said. Meanwhile, the pretax cost of the initial phase of the cost-cutting program is expected to range from $3.5 billion to $4.3 billion, much of it in severance packages for employees."

9 Jul 2010

Merck details global restructuring program

Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.

9 Jul 2010

WHO report examines donors response to developing countries during H1N1 pandemic

CIDRAP News examines a recently-released WHO report on how donor countries and organizations have responded to the needs of developing countries during the H1N1 (swine flu) pandemic. In September, the WHO estimated the "64 'least-resourced countries' needed a total of $1.48 billion of aid for vaccine, medicines and supplies, laboratory and surveillance services, communications capacity, and other activities to respond to the pandemic," according to the news service.

9 Jul 2010

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Tropical disease specialist Joseph Vinetz, MD, of the University of California, San Diego School of Medicine will lead an ambitious multi-national effort to help control and eventually conquer malaria, establishing a new Peruvian/Brazilian International Center of Excellence in Malaria Research Center with a seven-year, $9.2 million grant from the National Institutes of Health.

9 Jul 2010

Media outlets examine efforts to tackle HIV/AIDS worldwide

Ahead of the International AIDS Conference, set for July 18-23 in Vienna, Austria, Reuters features an interview with Gottfried Hirnschall, the new director of the WHO's HIV Department, who speaks of the need for current funds for the global HIV/AIDS programs to be used more efficiently to achieve universal access to treatment for all HIV/AIDS patients.

9 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

NIAID names Case Western Reserve University as International Center of Excellence for Malaria Research

Wall Street Journal essay examines historical efforts to control malaria

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Diabetes reform plans do not please the AMA

UM researcher uses computer algorithms to develop vaccines for new strains of influenza viruses

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Merck to lay off 15 percent of workers, close plants, research facilities

Merck details global restructuring program

WHO report examines donors response to developing countries during H1N1 pandemic

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Media outlets examine efforts to tackle HIV/AIDS worldwide

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in